G. Tirucherai

发表

Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)

J. Goldin, L. Lancaster, T. Maher, 2021, BMJ Open Respiratory Research.

Prodrug based optimal drug delivery via membrane transporter/receptor

A. Mitra, G. Tirucherai, C. Yang, 2001, Expert opinion on biological therapy.

Developing a Natural History Progression Model for Duchenne Muscular Dystrophy Using the Six‐Minute Walk Test

P. Chan, M. Abutarif, G. Tirucherai, 2017, CPT: pharmacometrics & systems pharmacology.

Functional differences in nucleoside and nucleobase transporters expressed on the rabbit corneal epithelial cell line (SIRC) and isolated rabbit cornea

S. Majumdar, A. Mitra, G. Tirucherai, 2003, AAPS PharmSci.

Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis

C. Frost, Jessie Wang, R. Boyd, 2016, Journal of clinical pharmacology.

Pegbelfermin (BMS‐986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study

B. Neuschwander‐Tetri, G. Tirucherai, E. Charles, 2018, Obesity.

Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial

Nikolaus R. McFarland, S. Haeberlein, M. Grossman, 2019, The Lancet Neurology.

The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis.

M. Karsdal, B. Neuschwander‐Tetri, Z. Goodman, 2021, Contemporary clinical trials.

Prodrug strategies in nasal drug delivery

A. Mitra, I. Pezron, S. Duvvuri, 2002 .

Evaluating a Multiscale Mechanistic Model of the Immune System to Predict Human Immunogenicity for a Biotherapeutic in Phase 1

Craig J. Thalhauser, A. Nayeem, B. Desilva, 2019, The AAPS Journal.

Prodrugs in nasal drug delivery

A. Mitra, G. Tirucherai, Chun Yang, 2001, Expert opinion on biological therapy.

Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA1) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases.

C. Chu, S. Jusuf, Yanou Yang, 2021, Journal of medicinal chemistry.

Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis

A. Sanyal, C. Mcnaney, B. Decato, 2021, JHEP reports : innovation in hepatology.

MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity.

C. Chu, E. A. Brown, D. Gordon, 2022, Cell metabolism.

BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial

M. Karsdal, Z. Goodman, U. Kavita, 2021, Hepatology.

A randomized, single ascending dose study of intravenous BIIB092 in healthy participants

M. Grundman, M. Ahlijanian, I. Qureshi, 2018, Alzheimer's & dementia.

Effect of Activated Charcoal on Apixaban Pharmacokinetics in Healthy Subjects

Giridhar Tirucherai, Charles Frost, C. Frost, 2013, American Journal of Cardiovascular Drugs.

Corneal permeation of ganciclovir: mechanism of ganciclovir permeation enhancement by acyl ester prodrug design.

A. Mitra, G. Tirucherai, C. Dias, 2002, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Effect of hydroxypropyl beta cyclodextrin complexation on aqueous solubility, stability, and corneal permeation of acyl ester prodrugs of ganciclovir

A. Mitra, G. Tirucherai, 2003, AAPS PharmSciTech.

Safety, tolerability, and pharmacokinetics of BMS-986263/ND-L02-s0201, a novel targeted lipid nanoparticle delivering HSP47 siRNA, in healthy participants: A randomised, placebo-controlled, double-blind, phase 1 study

U. Kavita, B. Soule, G. Tirucherai, 2018 .

Evaluating a Multiscale Mechanistic Model of the Immune System to Predict Human Immunogenicity for a Biotherapeutic in Phase 1

Craig J. Thalhauser, A. Nayeem, B. Desilva, 2019, The AAPS Journal.

Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitus

F. LaCreta, D. Boulton, G. Tirucherai, 2016, Diabetes, obesity & metabolism.

BMS-986278, A Lysophosphatidic Acid 1 (LPA1) Receptor Antagonist, in Healthy Participants: A Single/Multiple Ascending Dose (SAD/MAD) and Japanese MAD (JMAD) Phase 1 Study

J. Taubel, G. Klinger, G. Tirucherai, 2020 .

Mitigation of Adverse Clinical Events of a Narrow Target Therapeutic Index Compound through Modified Release Formulation Design: An in Vitro, in Vivo, in Silico, and Clinical Pharmacokinetic Analysis.

M. Hussain, J. Crison, P. Timmins, 2015, Molecular pharmaceutics.

Novel approaches to nasal delivery of peptides and proteins

A. Mitra, I. Pezron, G. Tirucherai, 2002 .

P315 Population pharmacokinetics and pharmacodynamics of ozanimod in ulcerative colitis

D. Tatosian, S. Harris, J. Lavigne, 2021, Journal of Crohn's & Colitis.

Reflecting on a decade of metabolite screening and monitoring.

Jian Wang, Mark E Arnold, Anne-Françoise Aubry, 2014, Bioanalysis.

Synthesis, stereoselective enzymatic hydrolysis, and skin permeation of diastereomeric propranolol ester prodrugs.

A. Mitra, G. Tirucherai, Chandrasekhar Udata, 1999, Journal of pharmaceutical sciences.

Pegbelfermin in patients with nonalcoholic steatohepatitis and stage 3 fibrosis (FALCON 1): a randomized phase 2b study.

B. Neuschwander‐Tetri, Z. Goodman, A. Sanyal, 2023, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis (FALCON 2): a randomized phase 2b study.

B. Neuschwander‐Tetri, Z. Goodman, A. Sanyal, 2023, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.